Published in AIDS Weekly, October 16th, 2006
According to a recent report from the United States, "The long-term adverse effects, expense, and difficulty of adherence to antiretroviral regimens have led to studies of simpler maintenance therapies.
"Maintenance therapy with ritonavir-boosted atazanavir alone is a possible option because of low pill burden, once-daily dosing, safety, and unique resistance profile."
S. Swindells and colleagues at the University of Nebraska Medical Center conducted a study to "assess whether simplified maintenance therapy with atazanavir-ritonavir alone...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.